ArticleScientific reports2025
The effect of high-dose long-term therapy of intravenous immunoglobulins in autoimmune autonomic and sensory small fiber neuropathy: a retrospective open-label controlled study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Intravenous Immunoglobulins (IVIG) are used to treat autoimmune autonomic and sensory small fiber neuropathy (ASFN). The long-term effects of a high immunomodulatory dose of IVIG in ASFN remain unclear. This retrospective controlled study evaluated the long-term effects of high dose (2 g/kg/monthly) IVIG compared to usual treatment in patients with ASFN. Inclusion criteria were: Survey of Autonomic Symptoms (SAS) score ≥ 10, abnormal autonomic testing and skin biopsy, and positive inflammatory/autoimmune markers or a history of acute illness preceding autonomic symptoms. Quantitative Scale for Grading of Cardiovascular Autonomic Reflex Tests and Small Fibers from Skin Biopsies (QASAT) was used to grade tests. Patients were treated with IVIG until their condition improved and reached a plateau. Linear models controlling for baseline were used to estimate the effect of IVIG. 41 ASFN patients were treated with IVIG and compared to 66 ASFN control patients treated with usual care. Both groups had evaluations at baseline and at the end of the trial. The average time IVIG therapy improved ASFN and reached plateau was 2.25 ± 0.99 years. The adverse effects of IVIG were frequent (prevalence 93%) but tolerable in most patients. IVIG improved SAS (p < 0.001) and QASAT total (p < 0.001), cerebral blood flow (p = 0.002) and autonomic failure (p = 0.035) scores. SAS and QASAT autonomic failure scores worsened in controls. Skin biopsy improved in both arms, but improvement was greater (p = 0.017) in the IVIG arm. This study provides evidence supporting the beneficial effect of long-term high-dose IVIG therapy for ASFN. Placebo-controlled, double-blinded studies are required to confirm our findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.